MedTrace Logo

Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II

NCT02144948 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-02-14

No results posted yet for this study

Summary

This is a pilot study to investigate the effect of e.-coli-nissle as supporting therapy to antidiabetic standard care in patients with diabetes mellitus type II

Conditions

  • Diabetes Mellitus Type II

Interventions

DRUG

e.-coli-nissle

1 ml qd for 24 weeks

Sponsors & Collaborators

  • Ardeypharm GmbH

    collaborator INDUSTRY

  • GWT-TUD GmbH

    lead OTHER

Principal Investigators

  • Antje Bergmann, Prof.Dr.med. · Carus Hausarztpraxis on behalf of GWT-TUD GmbH

  • Stefan R. Bornstein, Prof.Dr.med · Universitätsklinikum Dresden on behalf of GWT-TUD GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02144948 on ClinicalTrials.gov